Latest Innovation News

The Calmer Co has reported a robust 26% increase in quarterly sales, driven by strong growth in Australia and the US, alongside a significant 39% reduction in cash used in operations, signaling clear progress toward profitability.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.

xReality Group (XRG) has reported robust growth driven by its flagship Operator XR training system, securing a landmark $5.7 million contract with the Texas Department of Public Safety and unveiling ambitious plans for new product launches and global expansion.

xReality Group Limited delivered a record-breaking first quarter in FY26, driven by a landmark $5.7 million contract with the Texas Department of Public Safety and a rapidly growing US customer base.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

DUG Technology reports a robust start to FY26 with 19% revenue growth and a landmark SaaS and HPCaaS contract, marking key international milestones.

OD6 Metals has selected a cutting-edge rare earth processing flowsheet delivering ~75% recovery of key elements and completed metallurgical drilling at Splinter Rock, supported by a $2.5 million capital raise. The company also commenced Phase 2 drilling at its Gulf Creek Copper Project, maintaining a strong cash position.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.